The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Statins and Cancer Risk: A Meta-analysis
Abstract
CONTEXT: Statins are cholesterol-lowering drugs that have been proven in randomized controlled trials to prevent cardiac events. Recent retrospective analyses have suggested that statins also prevent cancer. OBJECTIVES: To investigate the effect of statin therapy on cancer incidence and cancer death and to analyze the effect of statins on specific cancers and the effect of statin lipophilicity or derivation. DATA SOURCES: A systematic literature search of MEDLINE, EMBASE, CINAHL, Web of Science, CANCERLIT, and the Cochrane Systematic Review Database through July 2005 was conducted using specific search terms. A review of cardiology and cancer abstracts and manual review of references was also performed. STUDY SELECTION: Twenty-seven of the 8943 articles (n = 86,936 participants) initially identified met the inclusion criteria, reporting 26 randomized controlled trials of statins, with a mean duration of follow-up of at least 1 year, enrolling a minimum of 100 patients, and reporting data on either cancer incidence (n = 20 studies) or cancer death (n = 22 studies). DATA EXTRACTION: All data were independently extracted by 3 investigators using a standardized data abstraction tool. Weighted averages were reported as odds ratios (ORs) with 95% confidence intervals (CIs) using a random-effects model (DerSimonian and Laird methods). Statistical heterogeneity scores were assessed with the Q statistic. DATA SYNTHESIS: In meta-analyses including 6662 incident cancers and 2407 cancer deaths, statins did not reduce the incidence of cancer (OR, 1.02; 95% CI, 0.97-1.07) or cancer deaths (OR, 1.01; 95% CI, 0.93-1.09). No reductions were noted for any individual cancer type. This null effect on cancer incidence persisted when only hydrophilic, lipophilic, naturally derived, or synthetically derived statins were evaluated. CONCLUSIONS: Statins have a neutral effect on cancer and cancer death risk in randomized controlled trials. We found that no type of cancer was affected by statin use and no subtype of statin affected the risk of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043545 · Cited by 2,614
Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Brown, B. G., Ganz, P., Vogel, R. A., Crowe, T., Howard, G., Cooper, C. J., Brodie, B., et al. (2004) · JAMA · doi:10.1001/jama.291.9.1071 · Cited by 2,361
Cited by
Systematic reviews: CRD's guidance for undertaking reviews in health care
Tacconelli, E. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70065-7 · Cited by 3,245
Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D.-W., Chevaile, A., Cobbe, S. M., Grönhagen-Riska, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810177 · Cited by 2,036
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Shared Risk Factors in Cardiovascular Disease and Cancer
Koene, R. J., Prizment, A. E., Blaes, A., & Konety, S. H. (2016) · Circulation · doi:10.1161/circulationaha.115.020406 · Cited by 1,494
Santos, C. R., & Schulze, A. (2012) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08644.x · Cited by 1,335
Statin Adverse Effects: A Review of the Literature and Evidence for a Mitochondrial Mechanism
Golomb, B. A., & Evans, M. A. (2008) · American Journal of Cardiovascular Drugs · doi:10.2165/0129784-200808060-00004 · Cited by 677
Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention
Butler, L. M., Perone, Y., Dehairs, J., Lupien, L. E., de Laat, V., Talebi, A., Loda, M., Kinlaw, W. B., & Swinnen, J. V. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.013 · Cited by 589
Chou, R., Dana, T., Blazina, I., Daeges, M., & Jeanne, T. L. (2016) · JAMA · doi:10.1001/jama.2015.15629 · Cited by 568
Hippisley-Cox, J., & Coupland, C. (2010) · BMJ · doi:10.1136/bmj.c2197 · Cited by 512
Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials
Sipahi, I., Debanne, S. M., Rowland, D. Y., Simon, D. I., & Fang, J. C. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70106-6 · Cited by 481
Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer
Gazzerro, P., Proto, M. C., Gangemi, G., Malfitano, A. M., Ciaglia, E., Pisanti, S., Santoro, A., Laezza, C., & Bifulco, M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004994 · Cited by 457
Singh, S., Singh, P. P., Singh, A. G., Murad, M. H., & Sanchez, W. (2013) · Gastroenterology · doi:10.1053/j.gastro.2012.10.005 · Cited by 452
p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression
Moon, S.-H., Huang, C.-H., Houlihan, S. L., Regunath, K., Freed-Pastor, W. A., Morris, J. P., Tschaharganeh, D. F., Kastenhuber, E. R., Barsotti, A. M., Culp-Hill, R., et al. (2019) · Cell · doi:10.1016/j.cell.2018.11.011 · Cited by 435
Long-term follow-up of the West of Scotland Coronary Prevention Study
Ford, I., Murray, H., Packard, C. J., Shepherd, J., Macfarlane, P. W., & Cobbe, S. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065994 · Cited by 416
Statin Drugs and Risk of Advanced Prostate Cancer
Platz, E. A., Leitzmann, M. F., Visvanathan, K., Rimm, E. B., Stampfer, M. J., Willett, W. C., & Giovannucci, E. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj499 · Cited by 406
Statin Prescriptions and Breast Cancer Recurrence Risk: A Danish Nationwide Prospective Cohort Study
Ahern, T. P., Pedersen, L., Tarp, M., Cronin-Fenton, D. P., Garne, J. P., Silliman, R. A., Sorensen, H. T., & Lash, T. L. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr291 · Cited by 387
Targeting cancer-promoting inflammation — have anti-inflammatory therapies come of age?
Hou, J., Karin, M., & Sun, B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00459-9 · Cited by 366
Cholesterol Treatment Trialists' (CTT) Collaboration (2012) · PLoS ONE · doi:10.1371/journal.pone.0029849 · Cited by 351
Statins for Secondary Prevention in Elderly Patients
Afilalo, J., Duque, G., Steele, R., Jukema, J. W., de Craen, A. J. M., & Eisenberg, M. J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.06.063 · Cited by 350
Targeting SREBP-1-driven Lipid Metabolism to Treat Cancer
Guo, D., Bell, E., Mischel, P., & Chakravarti, A. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990486 · Cited by 323
Avoidable flaws in observational analyses: an application to statins and cancer
Dickerman, B. A., García-Albéniz, X., Logan, R. W., Denaxas, S., & Hernán, M. A. (2019) · Nature Medicine · doi:10.1038/s41591-019-0597-x · Cited by 308
Statins for the primary prevention of cardiovascular disease
Taylor, F., Ward, K., Moore, T. H., Burke, M., Davey Smith, G., Casas, J. P., & Ebrahim, S. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub4 · Cited by 305
Naci, H., Brugts, J., & Ades, T. (2013) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.111.000071 · Cited by 292
Statins and the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus Infection
Tsan, Y.-T., Lee, C.-H., Wang, J.-D., & Chen, P.-C. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.0917 · Cited by 294
Chou, R., Cantor, A., Dana, T., Wagner, J., Ahmed, A. Y., Fu, R., & Ferencik, M. (2022) · JAMA · doi:10.1001/jama.2022.12138 · Cited by 287
Statins and cancer: A systematic review and meta-analysis
Kuoppala, J., Lamminpää, A., & Pukkala, E. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.06.025 · Cited by 285
Statin use and cancer risk: a comprehensive review
Boudreau, D. M., Yu, O., & Johnson, J. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740331003662620 · Cited by 274
Kelloff, G. J., Lippman, S. M., Dannenberg, A. J., Sigman, C. C., Pearce, H. L., Reid, B. J., Szabo, E., Jordan, V. C., Spitz, M. R., Mills, G. B., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1104 · Cited by 270
Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial
Bjarnadottir, O., Romero, Q., Bendahl, P.-O., Jirström, K., Rydén, L., Loman, N., Uhlén, M., Johannesson, H., Rose, C., Grabau, D., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2473-6 · Cited by 230
Comparative Effectiveness of Generic and Brand-Name Statins on Patient Outcomes: A Cohort Study
Gagne, J. J., Choudhry, N. K., Kesselheim, A. S., Polinski, J. M., Hutchins, D., Matlin, O. S., Brennan, T. A., Avorn, J., & Shrank, W. H. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2942 · Cited by 155
Lai, T., Wang, S., Xu, Z., Zhang, C., Zhao, Y., Hu, Y., Cao, C., Ying, S., Chen, Z., Li, W., et al. (2015) · Scientific Reports · doi:10.1038/srep08191 · Cited by 103
Do Statins Affect Androgen Levels in Men? Results from the Boston Area Community Health Survey
Hall, S. A., Page, S. T., Travison, T. G., Montgomery, R. B., Link, C. L., & McKinlay, J. B. (2007) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-0306 · Cited by 69
Seo, Y., Kim, J., Park, S. J., Park, J. J., Cheon, J. H., Kim, W. H., & Kim, T. I. (2020) · Cancers · doi:10.3390/cancers12092554 · Cited by 64
Gränsbo, K., Melander, O., Wallentin, L., Lindbäck, J., Stenestrand, U., Carlsson, J., & Nilsson, J. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.01.013 · Cited by 62
Lipworth, L., Fazio, S., Kabagambe, E., Munro, H., Nwazue, V., Tarone, R., McLaughlin, J., Blot, W., & Sampson, U. (2013) · Clinical Epidemiology · doi:10.2147/clep.s53492 · Cited by 26
Long-term use of anti-cholesterol drugs and cancer risks in a Japanese population
Okita, Y., Sobue, T., Zha, L., Kitamura, T., Iwasaki, M., Inoue, M., Yamaji, T., Tsugane, S., & Sawada, N. (2024) · Scientific Reports · doi:10.1038/s41598-024-53252-4 · Cited by 14
Metadata
- Authors
- Dale, K. M., Coleman, C. I., Henyan, N. N., Kluger, J., & White, C. M.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2006-01-04
- Volume
- 295
- Issue
- 1
- Pages
- 74
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2043263931
- Cited by
- 599
- References
- 46
- FWCI
- 21.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.